View all cases
UPC APP 68658/2024
Dec 30, 2024·EP2501384 · METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY
- Case details
- StatusCase Closed (Claim dismissed)ActionGenericCategoryFile-access requests (R. 262.1(b))
- Parties
- Respondents
- Accord Healthcare B.V.Operating co.
- Accord Healthcare S.L.U.Operating co.
- ACCORD HEALTHCARE LIMITEDOperating co.
- Novartis AGOperating co.
Representatives- Wim Maas-Taylor Wessing
- Gregory Bacon-Bristows
- Division
- Milan CD
- Technology
- ChemistryOrganic fine chemistry · Pharmaceuticals
- Language
- English
- First decided
- Feb 3, 2025
- EPO Opposition
- Fresenius Kabi Deutschland GmbHAdmissible2016-11-14
- Hamm&Wittkopp Patentanwälte PartmbBAdmissible2016-11-17
- Teva Pharmaceutical Industries LtdAdmissible2016-11-17
- Intas Pharmaceuticals Ltd.Admissible2016-11-17
- Generics (U.K.) LimitedAdmissible2016-11-17
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.Admissible2016-11-17
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Milan CD | Locked |
| Judge Andrea Postiglione | Locked |
| Judge Marije Knijff | Locked |
| Judge Oliver Werner | Locked |
At the UPC: STADAPHARM GmbH (10 cases)·Accord Group (8 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 1 other proceedings
1 other defendants litigating the same or a related patent
Decisions
- 2025-02-03Application RoP262.1 (b)Public
Summary: Application by STADAPHARM GmbH for public access to case documents under R.262.1(b) RoP (separate application number for the same underlying proceedings UPC_CFI_698/2024, Milan Central Division). Outcome identical to companion order: STADAPHARM's request to access documents was dismissed; NOVARTIS's request for legal cost compensation was dismissed. This appears to be the same decision issued under a different application reference number.
Show the legal issues (4)
- Public access to court documents R.262.1(b) RoP
- Primary purpose of access request
- Integrity of proceedings
- R.4.1 RoP digital signature requirements
Documents
| Document title | Date | Public |
|---|---|---|
| Exhibit TW 0 - Payment Court Fees | 2025-02-19 | Not public |
| Order 3 Februar 2025 | 2025-02-19 | Not public |
| 2025 02 18 - Appeal_signed | 2025-02-19 | Not public |
| Exhibit TW 2 | 2025-02-19 | Not public |
| Appeal Pleading | 2025-02-19 | Not public |
| Exhibit TW 3 | 2025-02-19 | Not public |
| Exhibit TW 2a | 2025-02-19 | Not public |
| Outcome of the Order | 2025-02-03 | Not public |
| ORDER 3rd February | 2025-02-03 | Public |
| Outcome of the Order | 2025-02-03 | Not public |
| ORDER 3rd February | 2025-02-03 | Public |
| Template-Order | 2025-02-03 | Not public |
| Receipt | 2025-01-24 | Not public |
| Reply by Applicant | 2025-01-24 | Not public |
| Exhibit TW 1 | 2025-01-24 | Not public |
| Novartis reply to Stadapharm R.262(1)b request | 2025-01-17 | Not public |
| Comments | 2025-01-17 | Not public |
| ORDER 02.01.25 | 2025-01-02 | Not public |
| Template-Order | 2025-01-02 | Not public |
| 2024 12 30 - Request RoP 262(1)b_signed | 2024-12-30 | Not public |